211 related articles for article (PubMed ID: 17949520)
1. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
2. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma.
Rini BI; Rathmell WK
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):741s-746s. PubMed ID: 17255303
[TBL] [Abstract][Full Text] [Related]
3. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.
Djordjevic G; Mozetic V; Mozetic DV; Licul V; Ilijas KM; Mustac E; Oguic R; Fuckar Z; Jonjic N
Pathol Res Pract; 2007; 203(2):99-106. PubMed ID: 17270362
[TBL] [Abstract][Full Text] [Related]
5. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
8. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
Al-Dissi AN; Haines DM; Singh B; Kidney BA
Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Keedy VL; Sandler AB
Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis.
Avnet S; Cenni E; Perut F; Granchi D; Brandi ML; Giunti A; Baldini N
Int J Oncol; 2007 Feb; 30(2):469-76. PubMed ID: 17203230
[TBL] [Abstract][Full Text] [Related]
12. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma.
Jacobsen J; Grankvist K; Rasmuson T; Ljungberg B
BJU Int; 2006 May; 97(5):1102-8. PubMed ID: 16643499
[TBL] [Abstract][Full Text] [Related]
13. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
Rivet J; Mourah S; Murata H; Mounier N; Pisonero H; Mongiat-Artus P; Teillac P; Calvo F; Janin A; Dosquet C
Cancer; 2008 Jan; 112(2):433-42. PubMed ID: 18041056
[TBL] [Abstract][Full Text] [Related]
14. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
Fergelot P; Rioux-Leclercq N; Patard JJ
Prog Urol; 2005 Dec; 15(6):1021-9. PubMed ID: 16429647
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic therapy against gastrointestinal tract cancers.
Iwasaki J; Nihira S
Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
[TBL] [Abstract][Full Text] [Related]
17. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
[TBL] [Abstract][Full Text] [Related]
20. [Diffusion weighted MRI helps evaluate angiogenesis and vascular endothelial growth factor expression in prostate cancer].
Liu JG; Wang B; Wang XZ; Niu QL; Zhang Q
Zhonghua Nan Ke Xue; 2009 May; 15(5):403-8. PubMed ID: 19514550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]